

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

NCT07201129

Status	RECRUITING
Phase	Phase 3
Sponsor	Viatrix Innovation GmbH
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (1)

- Classification of systemic lupus erythematosus (SLE) made according to the 2019 European Alliance of Associations for Rheumatology / American College of Rheumatology (EULAR/ACR) criteria.

Exclusion (44)

- Active renal disease defined as urine protein/creatinine ratio ≥ 1 mg/mg, assessed on a 24h urine collection.
- eGFR ≥ 15 mL/min/1.73 m². Enrollment of participants with eGFR between ≥ 15 and < 30 mL/min/1.73 m² requires:
- a renal biopsy during the screening period showing sclerosis in $\geq 50\%$ of glomeruli,
- activity index ≥ 2 , and chronicity index < 4 , on the National Institutes for Health 2018 activity and chronicity indices. These indices must be assessed on the kidney biopsy dated less than 6 months prior to Screening and confirmed by a nephropathologist.
- Initiation of the induction therapy with the mandatory following background therapy:

... and 39 more (see full listing online)

Locations (6 total)

SouthCoast Research Center, Miami, Florida, United States
Allied Biomedical Research Institute, Miami, Florida, United States
ProfessionalResearchCenter INC, Miami, Florida, United States
... and 3 more locations